Methods for nuclear reprogramming of cells
US-2015086649-A1 · Mar 26, 2015 · US
Administration of a poly-oxygenated metal hydroxide to reduce the proliferation of carcinoma cells
US9682103B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9682103-B1 |
| Application number | US-201615346580-A |
| Country | US |
| Kind code | B1 |
| Filing date | Nov 8, 2016 |
| Priority date | Mar 30, 2016 |
| Publication date | Jun 20, 2017 |
| Grant date | Jun 20, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of treating a condition of a mammal, including a human individual and an animal, by intravenously administering a therapeutically effective amount of a poly -oxygenated metal hydroxide. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm. The poly-oxygenated metal hydroxide may be 75-90% colloid or crystalline solution with 10-25% addition of poly-oxygenated metal hydroxide particles.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a human individual, comprising: administering a therapeutically effective amount of a poly-oxygenated aluminum hydroxide composition to a human individual to reduce a proliferation of heptocarcinoma cells (HEPG-2), wherein the poly-oxygenated aluminum hydroxide composition comprises a clathrate containing free oxygen gas (O 2 ) molecules. 2. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition is administered intravenously. 3. The method as specified in claim 1 wherein the poly -oxygenated aluminum hydroxide composition comprises poly-oxygenated aluminum hydroxide particles having a diameter of less than or equal to 100 nm. 4. The method as specified in claim 1 wherein the poly -oxygenated aluminum hydroxide composition comprises poly-oxygenated aluminum hydroxide particles having a diameter of less than or equal to 1 um. 5. The method as specified in claim 1 wherein the poly -oxygenated aluminum hydroxide composition is a colloid solution with 10-25% addition of poly-oxygenated aluminum hydroxide. 6. The method as specified in claim 1 wherein the poly -oxygenated aluminum hydroxide composition is a crystalline solution with 10-25% addition of poly-oxygenated aluminum hydroxide. 7. The method as specified in claim 1 wherein the poly -oxygenated aluminum hydroxide composition has a concentration range of 0.1 mg/l to 1000 mg/l. 8. The method as specified in claim 1 wherein the poly -oxygenated aluminum hydroxide composition has poly-oxygenated aluminum hydroxide particles that are surface modified.
Assignees
Inventors
Classifications
Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
- A61K33/08Primary
Oxides; Hydroxides · CPC title
- A61K9/0026Primary
Blood substitute; Oxygen transporting formulations; Plasma extender · CPC title
Nanoparticle, i.e. structure having three dimensions of 100 nm or less · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9682103B1 cover?
- A method of treating a condition of a mammal, including a human individual and an animal, by intravenously administering a therapeutically effective amount of a poly -oxygenated metal hydroxide. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or…
- Who is the assignee on this patent?
- Univ Baylor
- What technology area does this patent fall under?
- Primary CPC classification A61K33/08. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).